Front. Cell. Infect. Microbiol. Frontiers in Cellular and Infection Microbiology Front. Cell. Infect. Microbiol. 2235-2988 Frontiers Media S.A. 10.3389/fcimb.2023.1226054 Cellular and Infection Microbiology Correction Corrigendum: Drug repurposing approach against chikungunya virus: an in vitro and in silico study Kasabe Bhagyashri 1 † Ahire Gunwant 2 † Patil Poonam 2 Punekar Madhura 2 Davuluri Kusuma Sai 2 Kakade Mahadeo 2 Alagarasu Kalichamy 2 Parashar Deepti 2 * Cherian Sarah 1 * 1 Bioinformatics Group, Indian Council of Medical Research (ICMR)-National Institute of Virology, Pune, Maharashtra, India 2 Dengue & Chikungunya Group, Indian Council of Medical Research (ICMR)-National Institute of Virology, Pune, Maharashtra, India

Edited and Reviewed by: Daniel Salamango, Stony Brook University, United States

*Correspondence: Deepti Parashar, deeptiparasharster@gmail.com; Sarah Cherian, sarahcherian100@gmail.com

†These authors have equally contributed to this work

 23 06 2023 2023 13 1226054 20 05 2023 22 05 2023 Copyright © 2023 Kasabe, Ahire, Patil, Punekar, Davuluri, Kakade, Alagarasu, Parashar and Cherian 2023 Kasabe, Ahire, Patil, Punekar, Davuluri, Kakade, Alagarasu, Parashar and Cherian

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A corrigendum on Drug repurposing approach against chikungunya virus: an in vitro and in silico study by Kasabe B, Ahire G, Patil P, Punekar M, Davuluri KS, Kakade M, Alagarasu K, Parashar D and Cherian S (2023) Front. Cell. Infect. Microbiol. 13:1132538. doi: 10.3389/fcimb.2023.1132538 chikungunya virus (CHIKV) drug repurposing structural and non-structural proteins in silico screening in vitro validation section-in-acceptance Molecular Viral Pathogenesis

In the published article, there was an error in Table 4 as published. The target for metyrapone was listed twice while the target for lomibuvir was missed. The corrected Table 4 and its caption [Molecular docking interactions of the nine FDA approved drugs with CHIKV structural and non-structural proteins based on the binding affinity values and best pose] appear below.

Molecular docking interactions of the nine FDA approved drugs with CHIKV structural and non-structural proteins based on the binding affinity values and best pose.

Compound Potential binding viral targets Docking score Binding energy(kcal/mol) Ligand Efficiency(kcal/ mol)
2-Fluroadenine (a)-6.966(b)-2.958 -37.69-25.51 -11.091-5.632
Doxorubicin (a)-4.76(b)-6.069(c)-3.547 -77.88-77.55-77.21 -13.179-15.343-13.297
Felbiac (a)-4.332(b)-6.115 -44.3-39.72 -11.74-10.529
Metyrapone (a)-4.358(b)-6.498 -51.12-50.81 -12.521-13.255
Enalprilat (a)-7.476(b)-4.02 -60.97-55.33 -14.452-11.234
Emetine (a)-4.086(b)-4.238 -74.25-71.81
Resveratrol (a)-6.22(b)-4.675 -56.45-47.43 -14.72-11.734
Lombubivir (a)-5.573(b)-4.759 -81.13-78.83

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.